▶ 調査レポート

世界のドロスピレノン・エチニルエストラジオール錠市場予測(~2028年):エチニルエストラジオール30μg、エチニルエストラジオール20μg

• 英文タイトル:Global Drospirenone and Ethinylestradiol Tablets Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが調査・発行した産業分析レポートです。世界のドロスピレノン・エチニルエストラジオール錠市場予測(~2028年):エチニルエストラジオール30μg、エチニルエストラジオール20μg / Global Drospirenone and Ethinylestradiol Tablets Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 / GIR-22E8793資料のイメージです。• レポートコード:GIR-22E8793
• 出版社/出版日:GlobalInfoResearch / 2022年5月
• レポート形態:英文、PDF、101ページ
• 納品方法:Eメール(2~3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
ドロスピレノン・エチニルエストラジオール錠市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のドロスピレノン・エチニルエストラジオール錠の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx%の成長率で成長すると予想されます。

ドロスピレノン・エチニルエストラジオール錠市場は種類と用途によって区分されます。2017年~2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・エチニルエストラジオール30μg、エチニルエストラジオール20μg

用途別セグメントは次のように区分されます。
・避妊、中等度にきび、月経前症候群(PMS)、月経前不快気分障害(PMDD)、月経困難症

世界のドロスピレノン・エチニルエストラジオール錠市場の主要な市場プレーヤーは以下のとおりです。
・Camber Pharmaceuticals、Aurobindo Pharma、Teva Generics、Glenmark Pharmaceuticals、Xiromed、Wellona Pharma、Barr Pharmaceuticals, Inc.、Hetero Drugs、MYLAN LABS LTD.、Bayer Weimar GmbH und Co. KG

地域別セグメントは次の地域・国をカバーします。
・北米(米国、カナダ、メキシコ)
・ヨーロッパ(ドイツ、フランス、イギリス、ロシア、イタリア)
・アジア太平洋(日本、中国、韓国、インド、東南アジア、オーストラリア)
・南アメリカ(ブラジル、アルゼンチン、コロンビア)
・中東およびアフリカ(サウジアラビア、UAE、エジプト、南アフリカ)

本調査レポートの内容は計15章あります。
・第1章では、ドロスピレノン・エチニルエストラジオール錠製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なドロスピレノン・エチニルエストラジオール錠メーカーの企業概要、2019年~2022年までのドロスピレノン・エチニルエストラジオール錠の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なドロスピレノン・エチニルエストラジオール錠メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年~2028年までの地域別ドロスピレノン・エチニルエストラジオール錠の販売量、売上、成長性を示しています。
・第5、6章では、2017年~2028年までのドロスピレノン・エチニルエストラジオール錠の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年~2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年~2028年までの主要地域でのドロスピレノン・エチニルエストラジオール錠市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびドロスピレノン・エチニルエストラジオール錠の産業チェーンを掲載しています。
・第13、14、15章では、ドロスピレノン・エチニルエストラジオール錠の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):Camber Pharmaceuticals、Aurobindo Pharma、Teva Generics、Glenmark Pharmaceuticals、Xiromed、Wellona Pharma、Barr Pharmaceuticals, Inc.、Hetero Drugs、MYLAN LABS LTD.、Bayer Weimar GmbH und Co. KG
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年:エチニルエストラジオール30μg、エチニルエストラジオール20μg
・用途別分析2017年-2028年:避妊、中等度にきび、月経前症候群(PMS)、月経前不快気分障害(PMDD)、月経困難症
・ドロスピレノン・エチニルエストラジオール錠の北米市場規模2017年-2028年:アメリカ、カナダ、メキシコ
・ドロスピレノン・エチニルエストラジオール錠のヨーロッパ市場規模2017年-2028年:ドイツ、イギリス、フランス、ロシア、イタリア
・ドロスピレノン・エチニルエストラジオール錠のアジア市場規模2017年-2028年:中国、日本、韓国、インド、東南アジア、オーストラリア
・ドロスピレノン・エチニルエストラジオール錠の南米市場規模2017年-2028年:ブラジル、アルゼンチン
・ドロスピレノン・エチニルエストラジオール錠の中東・アフリカ市場規模2017年-2028年:サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Drospirenone and Ethinylestradiol Tablets market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Drospirenone and Ethinylestradiol Tablets market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Birth Control accounting for % of the Drospirenone and Ethinylestradiol Tablets global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While With 30 μg Ethinylestradiol segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Drospirenone and Ethinylestradiol Tablets include Camber Pharmaceuticals, Aurobindo Pharma, Teva Generics, Glenmark Pharmaceuticals, and Xiromed, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Drospirenone and Ethinylestradiol Tablets market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
With 30 μg Ethinylestradiol
With 20 μg Ethinylestradiol
Market segment by Application can be divided into
Birth Control
Moderate Acne
Premenstrual Syndrome (PMS)
Premenstrual Dysphoric Disorder (PMDD)
Dysmenorrhea
The key market players for global Drospirenone and Ethinylestradiol Tablets market are listed below:
Camber Pharmaceuticals
Aurobindo Pharma
Teva Generics
Glenmark Pharmaceuticals
Xiromed
Wellona Pharma
Barr Pharmaceuticals, Inc.
Hetero Drugs
MYLAN LABS LTD.
Bayer Weimar GmbH und Co. KG
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drospirenone and Ethinylestradiol Tablets product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drospirenone and Ethinylestradiol Tablets, with price, sales, revenue and global market share of Drospirenone and Ethinylestradiol Tablets from 2019 to 2022.
Chapter 3, the Drospirenone and Ethinylestradiol Tablets competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drospirenone and Ethinylestradiol Tablets breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Drospirenone and Ethinylestradiol Tablets market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Drospirenone and Ethinylestradiol Tablets.
Chapter 13, 14, and 15, to describe Drospirenone and Ethinylestradiol Tablets sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Drospirenone and Ethinylestradiol Tablets Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drospirenone and Ethinylestradiol Tablets Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 With 30 μg Ethinylestradiol
1.2.3 With 20 μg Ethinylestradiol
1.3 Market Analysis by Application
1.3.1 Overview: Global Drospirenone and Ethinylestradiol Tablets Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Birth Control
1.3.3 Moderate Acne
1.3.4 Premenstrual Syndrome (PMS)
1.3.5 Premenstrual Dysphoric Disorder (PMDD)
1.3.6 Dysmenorrhea
1.4 Global Drospirenone and Ethinylestradiol Tablets Market Size & Forecast
1.4.1 Global Drospirenone and Ethinylestradiol Tablets Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Drospirenone and Ethinylestradiol Tablets Sales in Volume (2017-2028)
1.4.3 Global Drospirenone and Ethinylestradiol Tablets Price (2017-2028)
1.5 Global Drospirenone and Ethinylestradiol Tablets Production Capacity Analysis
1.5.1 Global Drospirenone and Ethinylestradiol Tablets Total Production Capacity (2017-2028)
1.5.2 Global Drospirenone and Ethinylestradiol Tablets Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Drospirenone and Ethinylestradiol Tablets Market Drivers
1.6.2 Drospirenone and Ethinylestradiol Tablets Market Restraints
1.6.3 Drospirenone and Ethinylestradiol Tablets Trends Analysis
2 Manufacturers Profiles
2.1 Camber Pharmaceuticals
2.1.1 Camber Pharmaceuticals Details
2.1.2 Camber Pharmaceuticals Major Business
2.1.3 Camber Pharmaceuticals Drospirenone and Ethinylestradiol Tablets Product and Services
2.1.4 Camber Pharmaceuticals Drospirenone and Ethinylestradiol Tablets Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Aurobindo Pharma
2.2.1 Aurobindo Pharma Details
2.2.2 Aurobindo Pharma Major Business
2.2.3 Aurobindo Pharma Drospirenone and Ethinylestradiol Tablets Product and Services
2.2.4 Aurobindo Pharma Drospirenone and Ethinylestradiol Tablets Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Teva Generics
2.3.1 Teva Generics Details
2.3.2 Teva Generics Major Business
2.3.3 Teva Generics Drospirenone and Ethinylestradiol Tablets Product and Services
2.3.4 Teva Generics Drospirenone and Ethinylestradiol Tablets Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Glenmark Pharmaceuticals
2.4.1 Glenmark Pharmaceuticals Details
2.4.2 Glenmark Pharmaceuticals Major Business
2.4.3 Glenmark Pharmaceuticals Drospirenone and Ethinylestradiol Tablets Product and Services
2.4.4 Glenmark Pharmaceuticals Drospirenone and Ethinylestradiol Tablets Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Xiromed
2.5.1 Xiromed Details
2.5.2 Xiromed Major Business
2.5.3 Xiromed Drospirenone and Ethinylestradiol Tablets Product and Services
2.5.4 Xiromed Drospirenone and Ethinylestradiol Tablets Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Wellona Pharma
2.6.1 Wellona Pharma Details
2.6.2 Wellona Pharma Major Business
2.6.3 Wellona Pharma Drospirenone and Ethinylestradiol Tablets Product and Services
2.6.4 Wellona Pharma Drospirenone and Ethinylestradiol Tablets Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Barr Pharmaceuticals, Inc.
2.7.1 Barr Pharmaceuticals, Inc. Details
2.7.2 Barr Pharmaceuticals, Inc. Major Business
2.7.3 Barr Pharmaceuticals, Inc. Drospirenone and Ethinylestradiol Tablets Product and Services
2.7.4 Barr Pharmaceuticals, Inc. Drospirenone and Ethinylestradiol Tablets Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Hetero Drugs
2.8.1 Hetero Drugs Details
2.8.2 Hetero Drugs Major Business
2.8.3 Hetero Drugs Drospirenone and Ethinylestradiol Tablets Product and Services
2.8.4 Hetero Drugs Drospirenone and Ethinylestradiol Tablets Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 MYLAN LABS LTD.
2.9.1 MYLAN LABS LTD. Details
2.9.2 MYLAN LABS LTD. Major Business
2.9.3 MYLAN LABS LTD. Drospirenone and Ethinylestradiol Tablets Product and Services
2.9.4 MYLAN LABS LTD. Drospirenone and Ethinylestradiol Tablets Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Bayer Weimar GmbH und Co. KG
2.10.1 Bayer Weimar GmbH und Co. KG Details
2.10.2 Bayer Weimar GmbH und Co. KG Major Business
2.10.3 Bayer Weimar GmbH und Co. KG Drospirenone and Ethinylestradiol Tablets Product and Services
2.10.4 Bayer Weimar GmbH und Co. KG Drospirenone and Ethinylestradiol Tablets Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Drospirenone and Ethinylestradiol Tablets Breakdown Data by Manufacturer
3.1 Global Drospirenone and Ethinylestradiol Tablets Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Drospirenone and Ethinylestradiol Tablets Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Drospirenone and Ethinylestradiol Tablets
3.4 Market Concentration Rate
3.4.1 Top 3 Drospirenone and Ethinylestradiol Tablets Manufacturer Market Share in 2021
3.4.2 Top 6 Drospirenone and Ethinylestradiol Tablets Manufacturer Market Share in 2021
3.5 Global Drospirenone and Ethinylestradiol Tablets Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Drospirenone and Ethinylestradiol Tablets Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Drospirenone and Ethinylestradiol Tablets Market Size by Region
4.1.1 Global Drospirenone and Ethinylestradiol Tablets Sales in Volume by Region (2017-2028)
4.1.2 Global Drospirenone and Ethinylestradiol Tablets Revenue by Region (2017-2028)
4.2 North America Drospirenone and Ethinylestradiol Tablets Revenue (2017-2028)
4.3 Europe Drospirenone and Ethinylestradiol Tablets Revenue (2017-2028)
4.4 Asia-Pacific Drospirenone and Ethinylestradiol Tablets Revenue (2017-2028)
4.5 South America Drospirenone and Ethinylestradiol Tablets Revenue (2017-2028)
4.6 Middle East and Africa Drospirenone and Ethinylestradiol Tablets Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Drospirenone and Ethinylestradiol Tablets Sales in Volume by Type (2017-2028)
5.2 Global Drospirenone and Ethinylestradiol Tablets Revenue by Type (2017-2028)
5.3 Global Drospirenone and Ethinylestradiol Tablets Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Drospirenone and Ethinylestradiol Tablets Sales in Volume by Application (2017-2028)
6.2 Global Drospirenone and Ethinylestradiol Tablets Revenue by Application (2017-2028)
6.3 Global Drospirenone and Ethinylestradiol Tablets Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Drospirenone and Ethinylestradiol Tablets Sales by Type (2017-2028)
7.2 North America Drospirenone and Ethinylestradiol Tablets Sales by Application (2017-2028)
7.3 North America Drospirenone and Ethinylestradiol Tablets Market Size by Country
7.3.1 North America Drospirenone and Ethinylestradiol Tablets Sales in Volume by Country (2017-2028)
7.3.2 North America Drospirenone and Ethinylestradiol Tablets Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Drospirenone and Ethinylestradiol Tablets Sales by Type (2017-2028)
8.2 Europe Drospirenone and Ethinylestradiol Tablets Sales by Application (2017-2028)
8.3 Europe Drospirenone and Ethinylestradiol Tablets Market Size by Country
8.3.1 Europe Drospirenone and Ethinylestradiol Tablets Sales in Volume by Country (2017-2028)
8.3.2 Europe Drospirenone and Ethinylestradiol Tablets Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Drospirenone and Ethinylestradiol Tablets Sales by Type (2017-2028)
9.2 Asia-Pacific Drospirenone and Ethinylestradiol Tablets Sales by Application (2017-2028)
9.3 Asia-Pacific Drospirenone and Ethinylestradiol Tablets Market Size by Region
9.3.1 Asia-Pacific Drospirenone and Ethinylestradiol Tablets Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Drospirenone and Ethinylestradiol Tablets Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Drospirenone and Ethinylestradiol Tablets Sales by Type (2017-2028)
10.2 South America Drospirenone and Ethinylestradiol Tablets Sales by Application (2017-2028)
10.3 South America Drospirenone and Ethinylestradiol Tablets Market Size by Country
10.3.1 South America Drospirenone and Ethinylestradiol Tablets Sales in Volume by Country (2017-2028)
10.3.2 South America Drospirenone and Ethinylestradiol Tablets Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Drospirenone and Ethinylestradiol Tablets Sales by Type (2017-2028)
11.2 Middle East & Africa Drospirenone and Ethinylestradiol Tablets Sales by Application (2017-2028)
11.3 Middle East & Africa Drospirenone and Ethinylestradiol Tablets Market Size by Country
11.3.1 Middle East & Africa Drospirenone and Ethinylestradiol Tablets Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Drospirenone and Ethinylestradiol Tablets Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Drospirenone and Ethinylestradiol Tablets and Key Manufacturers
12.2 Manufacturing Costs Percentage of Drospirenone and Ethinylestradiol Tablets
12.3 Drospirenone and Ethinylestradiol Tablets Production Process
12.4 Drospirenone and Ethinylestradiol Tablets Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Drospirenone and Ethinylestradiol Tablets Typical Distributors
13.3 Drospirenone and Ethinylestradiol Tablets Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer